AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05887843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
Study NCT05887843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochloride
Description: Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
Study NCT06339411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin post-mechanical thrombectomy, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
Study NCT04735692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth or quadrant SRP
Description: Full mouth or quadrant SRP
Study NCT04735692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Full mouth or quadrant SRP
Description: Full mouth or quadrant SRP
Study NCT04015921 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
Study NCT05299931 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab
Description: dose escalation from every 8 weeks to every 4 weeks only in arm 2
Study NCT04532190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS)
Study NCT04532190 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS)
Study NCT06445842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The protocol involves a 10-minute warm-up and cool-down session, followed by two sets of high-intensity circuit training exercises (bench press, squats, overhead press, calf raising, barbell row, deadlifts) that last 12 minutes each (6 stations×2sets). There will be a 3-minute break between the exercise sets. The heart rate required during the exercise will be between 70-90% of their maximum capacity and a pre-scale rate of 7.5. The intensity of the exercise will be progressive each two weeks, commencing at 50% of their one rep max and increasing to 80% in their last week. During the initial phase, participants will be required to complete eight reps for each exercise. We will encourage them to increase their intensity level every two weeks.
Study NCT06445842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: This group will need to maintain their sedentary lifestyle without changing their activity levels or diet
Study NCT04818645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASSERT Insertable Cardiac Monitor
Description: Subjects will be subcutaneously implanted with an Abbott ASSERT ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.
Study NCT04818645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Management and monitoring
Description: Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.
Study NCT05971823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: Subjective measures 1 is followed by product sampling that includes 5 self-directed ECIG/own brand cigarette puffs over 10 minutes. After sampling is complete participants complete subjective measures 2. Ten minutes after their sampling has been completed, they complete subjective measures 3 and the behavioral economic task(s). These activities are preceded and followed by cardiovascular response assessment.
Study NCT05971823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: Subjective measures 1 is followed by product sampling that includes 5 self-directed ECIG/own brand cigarette puffs over 10 minutes. After sampling is complete participants complete subjective measures 2. Ten minutes after their sampling has been completed, they complete subjective measures 3 and the behavioral economic task(s). These activities are preceded and followed by cardiovascular response assessment.
Study NCT06318442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Oral Product
Description: Oral semaglutide 3mg once uptitrated to twice daily
Study NCT06318442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Oral Tablet
Description: Metformin modified release tablets 500mg once daily uptitrated to twice daily).
Study NCT06318442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT05583214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: 8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
Study NCT05583214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg
Description: 8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
Study NCT05583214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be given IV stat to the group after induction of spinal anesthesia
Study NCT04933201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Perioperative musical intervention
Study NCT04933201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine perioperative treatment
Description: Routine perioperative treatment
Study NCT06397274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stemchymal
Description: Patients will receive Stemchymal® through intravenous infusion
Study NCT06216808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperQure Renal Denervation System
Description: The HyperQure RDN System consists of a generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessel is planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN is also performed on the branch or accessory vessel confirmed to be suitable for the procedure by CTA.
Study NCT06397274 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo through intravenous infusion
Study NCT06439823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiMyo®/Syde®
Description: Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.
Study NCT05011123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells)
Description: Powder and diluent for suspension for injection - Subcutaneous
Study NCT05011123 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine
Description: Powder and diluent for suspension for injection - Subcutaneous
Study NCT05465512 — intervention group
Intervention type: OTHER
Intervention: response to neoadjuvant chemotherapy
Description: Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
Study NCT06320925 — intervention group
Intervention type: DEVICE
Intervention: Standard of Care Treatment
Description: Subject has undergone joint space repair using one of the study devices and meets eligibility criteria
Study NCT04916119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI323
Description: In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
Study NCT05050578 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Commercially available, silicone hydrogel, spherical contact lenses used as indicated
Study NCT05050578 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Commercially available, silicone hydrogel, spherical contact lenses used as indicated
Study NCT05050578 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution
Study NCT03987126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk Oligosaccharides (HMO)
Description: Sachet containing 10 grams of HMO
Study NCT03987126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachet manufactured to mimic 10g of HMO
Study NCT05144308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Images of the operated eye (s)
Description: Through the operating microscope or a slit lamp, dilated pupil. Taken on the day of surgery (D0) and at 1 week, 1 month and 3 months post-op
Study NCT06070584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,
Description: aerobic exercises with moderate intensity in the form of walking on electrical treadmill
Study NCT06070584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,
Description: aerobic exercises with moderate intensity in the form of walking on electrical treadmill
Study NCT04740203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting CD19 and CD22
Description: Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
Study NCT05022095 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Diverse questionnaires have to be filled in.
Study NCT05957302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
Study NCT05957302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
Study NCT05713006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib Oral Product
Description: Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
Study NCT05870956 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study NCT05444725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stage of Decision Making
Description: Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
Study NCT05444725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Choice framing
Description: Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
Study NCT05444725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Opportunity Framing
Description: Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
Study NCT06038344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten-free food guide teaching
Description: Teaching the gluten-free food guide will be done over Zoom within 1-2 weeks of the dietitian's standard of care teaching (group Zoom session). This teaching will take 30-45 minutes and will be conducted by a trained researcher. The investigators will use the gluten-free food guide as teaching materials with a focus on the GF plate model, the rationale for the GF plate model, nutritional consideration of gluten-free diet and content related to the additional 24 teaching materials (e.g. folate, fibre, eating out, school lunches etc.) contained within the guide. Individualized dietary suggestions based on participants' food records will also be provided.
Study NCT05494008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean herbal medicine treatment
Description: Korean herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes.
Study NCT05494008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Korean herbal medicine treatment
Description: acupuncture, pharmacoacupuncture, cupping, chuna
Study NCT04964544 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 5 mg rosuvastatin calcium with a Web App (combination product)
Description: The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool). Rosuvastatin calcium 5 mg will be taken orally, 1 tablet daily to use for lowering cholesterol, a key risk factor that can lead to heart disease.
Study NCT05495152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
Study NCT04715542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stibium metallicum praeparatum 6x
Description: Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
Study NCT04715542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
Study NCT05945615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.1% (Pf) Oph Soln Ud
Description: Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis.
Study NCT05945615 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free lubricating drops
Description: Over the counter ophthalmic lubricating drop.
Study NCT04953338 — intervention group
Intervention type: OTHER
Intervention: Exposure of mental health condtion of interest
Description: Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
Study NCT05008029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In situ immobilization
Description: Immobilization with an above-elbow cast. A 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow supervised by a pediatric orthopedic surgeon will perform the procedure without reduction, sedation, or anesthesia. Analgesia will be administered with paracetamol at doses of 10-15 mg/kg/dose or tramadol 0.5-1mg/kg/dose. Supposing immobilization is not satisfactory, or the patient or family member does not authorize the procedure to be carried out by staff in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
Study NCT05008029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction under general anesthesia
Description: The participants will receive paracetamol at 10-15 mg/kg/dose or tramadol 0.5-1 mg/kg/dose for pain control until the time of surgery. Under general anesthesia, radius closed reduction, and above-elbow casting will be performed. After the reduction maneuvers, the radius reduction is satisfactory if the translation in the coronal and sagittal planes of less than 50% and angulation in the same planes is less than 10 °. If the radius does not remain reduced, it is unstable. Unstable fractures require percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block. The procedures will be carried out by a 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow under the supervision of a child orthopedist. Suppose reduction is not satisfactory or the patient or parent doesn´t authorize the procedure performed by personnel in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
Study NCT04958707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information including knowledge and skills related to dementia patient care
Description: The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.
Study NCT04958707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
Study NCT06137742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07868489
Description: Experimental Treatment
Study NCT06137742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-07868489
Description: Placebo
Study NCT05370586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve Group Block
Description: Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
Study NCT06065384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group: intensive motor training
Description: Intervention group: receive an extra 12 hours of motor training each week (distributed over the week) for 10 weeks. It will involve active and targeted motor training of all affected muscles of the upper limb below the level of the injury within the context of practice of functional activities. Interventions will be goal directed and individualized to the needs of each participant with a focus on training that addresses each person's specific motor problem, promoting motor learning as well as stimulating neural plasticity. All patients will continue to receive usual physiotherapy and usual rehabilitation.
Study NCT05370586 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Infrainguinal Fascia Iliaca Block
Description: Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
Study NCT06647667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIITS
Description: Frequency: HIIT will be in 2 supervised sessions per week for 12 weeks on the treadmill.~session duration from 30-40 min including the waming up and cooling down Intensity: HIIT included 4 minute intervals aiming 60-85% of heart rate reserve